Zenas Biopharma (NASDAQ:ZBIO – Get Free Report) is anticipated to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Zenas Biopharma to post earnings of ($0.92) per share for the quarter.
Zenas Biopharma Stock Performance
NASDAQ:ZBIO opened at $8.25 on Thursday. Zenas Biopharma has a 52-week low of $5.83 and a 52-week high of $26.25. The firm has a market cap of $344.84 million and a price-to-earnings ratio of -2.32.
Analyst Ratings Changes
Several research firms have issued reports on ZBIO. Guggenheim reaffirmed a “buy” rating and set a $45.00 price objective on shares of Zenas Biopharma in a report on Wednesday, March 12th. Wedbush began coverage on Zenas Biopharma in a report on Thursday. They set an “outperform” rating and a $35.00 price objective on the stock.
Zenas Biopharma Company Profile
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas Biopharma
- What is the Hang Seng index?
- Semtech Rallies on Earnings Beat—Is There More Upside?
- The 3 Best Retail Stocks to Shop for in August
- General Mills High-Yield Value: A Good Buy for Risk-Off Investors
- Trading Stocks: RSI and Why it’s Useful
- Why Archer Aviation Stock Could Soar After Palantir Partnership
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
